Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
analyzed, antitoxin, Appraisal, aqua, AstraZenca, baseline, begun, bezlotoxumab, break, Clostridium, commonly, diagnostic, diarrhea, difficile, docetaxel, draft, enzyme, escrow, Excellence, expression, Fl, grasoprevir, Hyo, Inhibition, instability, Lifetec, MACE, Marizev, microsatellite, NICE, omarigliptin, PCV, play, pneumococcal, Pneumovax, polyvalent, proportion, qualifying, revealed, role, Savior, session, Stockpile, stream, strength, strongly, tissue, topline, TPS, true, virtually, week, weighted
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10 Exhibit 10: Agreement Letter Between Merck & Co., Inc. and Bruce N. Kuhlik
- 31.1 Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.1 Exhibit 32.1: Section 1350 Certification of CEO
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
MRK similar filings
Filing view
External links